Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD)

Nephrology Dialysis Transplantation

Volumn 24, Issue 8, 2009, Pages 2349-2353

  Zafar, Iram ^a   Belibi, Franck A ^a   He, Zhibin ^a   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Chronic kidney disease; Heart; MTOR; Polycystic kidney; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; HYPERTENSION; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; DISEASE MODELS, ANIMAL; HEART; HYPERTENSION; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; MALE; ORGAN SIZE; POLYCYSTIC KIDNEY DISEASES; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TIME FACTORS;

EID: 67651087241     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp129     Document Type: Article

References (24)

1. Gabow PA. Autosomal dominant polycystic kidney disease. N Engl J Med 1993; 329: 332-342
2. Tao Y, Kim J, Schrier RW et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease (PKD). J Am Soc Nephrol 2005; 16: 46-51
3. Wahl PR, Serra AL, Le Hir M et al. Inhibition ofmTORwith sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 2006; 21: 598-604
4. Wu M, Wahl PR, Le Hir M et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 2007; 30: 253-259
5. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006; 103: 5466-5471
6. Cowley BD Jr, Rupp JC, Muessel MJ et al. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 1997; 29: 265-272
7. Shi Y, Melnikov VY, Schrier RW et al. Downregulation of the calpain inhibitor protein calpastatin by caspases during renal ischemiareperfusion. Am J Physiol Renal Physiol 2000; 279: F509-F517
8. Ferrari S, Bandi HR, Hofsteenge J et al. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 1991; 266: 22770-22775
9. Flotow H, Thomas G. Substrate recognition determinants of the mitogen-activated 70K S6 kinase from rat liver. J Biol Chem 1992; 267: 3074-3078
10. Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350: 151-164
11. Trudel M, D'Agati V, Costantini F. C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 1991; 39: 665-671
12. Schaffner DL, Barrios R, Massey C et al. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 1993; 142: 1051-1060
13. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 3151-3171
14. Chapman AB, Johnson A, Gabow PA et al. The renin - angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096
15. Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. [Review] [65 refs]. J Am Soc Nephrol 2001; 12: 194-200
16. Ecder T, Edelstein CL, Chapman AB et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999; 14: 1113-1116
17. Kennefick TM, Al-Nimri MA, Oyama TT et al. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int 1999; 56: 2181-2190
18. Zafar I, Tao Y, Falk S et al. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007; 293: F854-F859
19. Fick-Brosnahan GM, Belz MM, McFann KK et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002; 39: 1127-1134
20. Shioi T, McMullen JR, Tarnavski O et al. Rapamycin attenuates loadinduced cardiac hypertrophy in mice. Circulation 2003; 107: 1664-1670
21. Proud CG: Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 2004; 63: 403-413
22. Paoletti E, Amidone M, Cassottana P et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52: 324-330
23. Cowley BD Jr, Gudapaty S, Kraybill AL et al. Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534
24. Schafer K, Gretz N, Bader M et al. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int 1994; 46: 134-152